Inhibition of Pyruvate Dehydrogenase Kinase Improves Pulmonary Arterial Hypertension in Genetically Susceptible Patients

Science Translational Medicine - United States
doi 10.1126/scitranslmed.aao4583
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Association for the Advancement of Science (AAAS)

Related search

Imatinib in Pulmonary Arterial Hypertension: C-Kit Inhibition

Pulmonary Circulation
PulmonaryRespiratory Medicine
2014English

Tyrosine Kinase Inhibitor–Induced Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2018English

Volume Management in Pulmonary Arterial Hypertension Patients: An Expert Pulmonary Hypertension Clinician Perspective

Pulmonary Therapy
2018English

Platelet Indices in Patients With Pulmonary Arterial Hypertension

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2011English

Pulmonary Arterial Hypertension in Patients Treated With Interferon

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2014English

Checkpoint Kinase 1 Promotes the Development of Pulmonary Arterial Hypertension

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2019English

Pulmonary Arterial Hypertension

Current Problems in Cardiology
MedicineCardiovascular MedicineCardiology
2011English

AZD7545, a Novel Inhibitor of Pyruvate Dehydrogenase Kinase 2 (PDHK2), Activates Pyruvate Dehydrogenase in Vivo and Improves Blood Glucose Control in Obese (Fa/Fa) Zucker Rats

Biochemical Society Transactions
Biochemistry
2003English

Long-Term Regulation of Pyruvate Dehydrogenase Complex. Evidence That Kinase-Activator Protein (KAP) Is Free Pyruvate Dehydrogenase Kinase

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
1991English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy